期刊
JOURNAL OF BONE AND MINERAL RESEARCH
卷 27, 期 5, 页码 963-974出版社
WILEY
DOI: 10.1002/jbmr.1570
关键词
OSTEOPOROSIS; LONG-TERM; DISCONTINUATION; FRACTURE; BONE MINERAL DENSITY; BONE TURNOVER MARKERS
资金
- Eli Lilly
- Merck
- Novartis
- Servier
- Amgen
- Pfizer
- Roche-GlaxoSmithKline
- MSD
- GSK
- Sanofi
- Warner Chilcott
- Roche (Switzerland)
- Amgen Inc.
- Procter Gamble
- sanofi-aventis
- Roche
- IDS
- Servier RD
- Acuitas
- Nycomed
- Novartis Pharma AG, Basel, Switzerland
Osteoporosis may be a lifelong condition. Robust data regarding the efficacy and safety of both long-term osteoporosis therapy and therapy discontinuation are therefore important. A paucity of clinical trial data regarding the long-term antifracture efficacy of osteoporosis therapies necessitates the use of surrogate endpoints in discussions surrounding long-term use and/or discontinuation. Long-term treatment (beyond 34 years) may produce further increases in bone mineral density (BMD) or BMD stability, depending on the specific treatment and the skeletal site. Bisphosphonates, when discontinued, are associated with a prolonged reduction in bone turnover markers (BTMs), with a very gradual increase to pretreatment levels within 3 to 60 months of treatment cessation, depending on the bisphosphonate used and the prior duration of therapy. In contrast, with nonbisphosphonate antiresorptive agents, such as estrogen and denosumab, BTMs rebound to above pretreatment values within months of discontinuation. The pattern of BTM change is generally mirrored by a more or less rapid decrease in BMD. Although the prolonged effect of some bisphosphonates on BTMs and BMD may contribute to residual benefit on bone strength, it may also raise safety concerns. Adequately powered postdiscontinuation fracture studies and conclusive evidence on maintenance or loss of fracture benefit is lacking for bisphosphonates. Similarly, the effects of rapid reversal of bone turnover upon discontinuation of denosumab on fracture risk remain unknown. Ideally, studies evaluating the effects of long-term treatment and treatment discontinuation should be designed to provide head-to-head offset data between bisphosphonates and nonbisphosphonate antiresorptive agents. In the absence of this, a clinical recommendation for physicians may be to periodically assess the benefits/risks of continuation versus discontinuation versus alternative management strategies. (c) 2012 American Society for Bone and Mineral Research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据